Arjun Agarwal, Senior Vice President of Finance at Oruka Therapeutics, Inc. (NASDAQ:ORKA), filed a Form 4 on September 21, 2026, disclosing the sale of 533 shares of common stock under a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Shares sold: Arjun Agarwal disposed of 533 shares of Oruka Therapeutics common stock on September 21, 2026.
  • Sale price: The shares were sold at $95.75 per share.
  • Remaining ownership: Following the transaction, Agarwal directly beneficially owns 14,219 shares.
  • Trading plan: The sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.
  • Transaction code: The transaction was coded "S" (sale) and marked as disposed of (D) in the filing.
  • Signatory: The form was signed by Paul Quinlan as attorney-in-fact for Arjun Agarwal.

Agarwal's Share Sale Details and Trading Plan Context

According to the Form 4 filing, Arjun Agarwal, Senior Vice President of Finance at Oruka Therapeutics, Inc., sold 533 shares of the company's common stock on September 21, 2026, at a price of $95.75 per share. The filing indicates the transaction was a direct disposition, coded "S" under Table I for non-derivative securities. No derivative securities transactions were reported in Table II.

The filing discloses that the sales were effected pursuant to a Rule 10b5-1 trading plan that Agarwal entered into on February 11, 2026. The Form 4 checkbox confirms the transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Following the reported sale, Agarwal directly beneficially owns 14,219 shares of Oruka Therapeutics common stock, according to the filing.

The form was filed by one reporting person and was signed by Paul Quinlan as attorney-in-fact for Arjun Agarwal, with a signature date of September 21, 2026. Oruka Therapeutics, Inc. is listed on NASDAQ under the ticker symbol ORKA, as stated on the filing's cover.

What Was Disclosed

The filing discloses a single open-market sale of 533 shares of Oruka Therapeutics common stock by SVP of Finance Arjun Agarwal at $95.75 per share on September 21, 2026, under a pre-established Rule 10b5-1 plan, leaving him with 14,219 shares directly owned.